References
- 1. UNAIDS. AIDS epidemic update: December 2009.
- 2. Rojanapithayakorn W. The 100% condom use programme in Asia. Reprod Health Matters. 2006; 14: 41-52.10.1016/S0968-8080(06)28270-3
- 3. Punyacharoensin N, Viwatwongkasem C. Trends in three decades of HIV/AIDS epidemic in Thailand by nonparametric backcalculation method. AIDS. 2009; 23:1143-52.
- 4. Johnston MI, Fauci AS. An HIV vaccine-challenges and prospects. N Engl J Med. 2008; 359:888-90.
- 5. Fauci AS, Johnston MI, Dieffenbach CW, Burton DR, Hammer SM, Hoxie JA, et al. HIV vaccine research: the way forward. Science. 2008; 321:530-2.
- 6. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008; 455:613-9.
- 7. Berkley SF, Koff WC. Scientific and policy challenges to development of an AIDS vaccine. Lancet. 2007; 370: 94-101.
- 8. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol. 2006; 7:19-23.
- 9. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF; rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005; 191:654-65.
- 10. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661-71.
- 11. Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008; 320:760-4.
- 12. Moore JP, Burton DR. Urgently needed: a filter for the HIV-1 vaccine pipeline. Nat Med. 2004; 10:769-71.
- 13. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don’t know, what we should know. Nat Med. 2004; 10:806-10.
- 14. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD81 cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994; 68, 6103-10.
- 15. Haynes BF, Shattock RJ. Critical issues in mucosal immunity for HIV-1 vaccine development. J Allergy Clin Immunol. 2008; 122:3-9.
- 16. Gupta SB, Jacobson LP, Margolick JB, Rinaldo CR, Phair JP, Jamieson BD, et al. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point. J Infect Dis. 2007; 4:546-50.
- 17. Mattapallil JJ, Douek DC, Buckler-White A, Montefiori D, Letvin NL, Nabel GJ, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med. 2006; 203: 1533-41.
- 18. Wilson NA, Reed J, Napoe GS, Piaskowski S, Szymanski A, Furlott J, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol. 2006; 80:5875-85.
- 19. Korber BT, Letvin NL, Haynes BF. T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces. J Virol. 2009; 83:8300-14. \10.1128/JVI.00114-09
- 20. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008; 14:617-21.
- 21. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS. 1997; 11 (Suppl A): S127-37.
- 22. Fast PE. Recent trends in clinical trials of vaccines to prevent HIV/AIDS. Curr Opin HIV AIDS. 2006; 1: 267-71.
- 23. Belyakov IM, Ahlers JD, Nabel GJ, Moss B, Berzofsky JA. Generation of functionally active HIV-1 specific CD8+ CTL in intestinal mucosa following mucosal, systemic or mixed prime-boost immunization. Virology. 2008; 381:106-15.
- 24. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Human Vaccines. 2009; 5:1-5.
- 25. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis. 2008; 46:1769-81.
- 26. Spearman P: HIV Vaccine Development. Lessons from the Past and Promise for the Future. Curr HIV Res. 2003; 1:101-20.
- 27. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007; 25:4085-92.
- 28. Harari A, Bart PA, Stohr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008; 205:63-77.
- 29. Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr. 2007; 45:20-7.
- 30. Vaccari M, Mattapallil J, Song K, Tsai WP, Hryniewicz A, Venzon D, et al. Reduced protection from simian immunodeficiency virus SIVmac251 infection afforded by memory CD8+ T cells induced by vaccination during CD4+ T-cell deficiency. J Virol. 2008; 82: 9629-38.
- 31. Engram JC, Dunham RM, Makedonas G, Vanderford TH, Sumpter B, Klatt NR, et al. Vaccine-induced, Simian Immunodeficiency Virus-specific CD8+ T cells reduce virus replication but do not protect from Simian Immunodeficiency Virus disease progression. J Immunol. 2009; 183:706-17.
- 32. Ramsburg E, Rose NF, Marx PA, Mefford M, Nixon DF, Moretto WJ, et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol. 2004; 78:3930-40.10.1128/JVI.78.8.3930-3940.2004
- 33. Amara RR, Villinger F, Altman JD, Lydy SL, O’Neil SP, Staprans SI, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 2001; 292:69-74.
- 34. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on ‘Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines’, 31 January-2 February 2006, IAVI, New York, USA. AIDS. 2007; 21:539-46.
- 35. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cellmediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, testof- concept trial. Lancet. 2008; 372:1881-93.
- 36. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept step study: a casecohort analysis. Lancet. 2008; 372:1894-905.
- 37. Gray G. Results from the Phambili (HVTN 503) study: a multicenter phase IIB test-of-concept study of the MRKad5 HIV-1 gag/pol/nef vaccine in South Africa. Presented at AIDS Vaccine 2008, Cape Town, South Africa, October 13-16, 2008.
- 38. Excler JL, Rida W, Priddy F, Fast P, Koff W. A strategy for accelerating the development of preventive AIDS vaccines. AIDS. 2007; 21:2259-63.
- 39. Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. HIV/AIDS preventive vaccine ‘prime-boost’ phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006; 20: 1471-9.
- 40. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N Engl J Med. 2009; 361:2209-20.
- 41. Pitisuttithum P. HIV vaccine research in Thailand: lessons learned. Expert Rev Vaccines. 2008; 7:311-7.10.1586/14760584.7.3.311
- 42. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr. 2007; 46:48-55.
- 43. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al. Antibodydependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/ AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005; 23:2522-9.10.1016/j.vaccine.2004.10.028
- 44. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, doubleblind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis. 2006; 194:1661-71.
- 45. Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004; 303:316.
- 46. Phogat S, Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des. 2007; 13:213-27.10.2174/138161207779313632
- 47. Montero M, van Houten NE, Wang X, Scott JK. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev. 2008; 72:54-84.10.1128/MMBR.00006-08
- 48. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature.2007; 446:1038-45.
- 49. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol. 2009; 83: 7337-48.
- 50. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326:285-9.
- 51. Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009; 15:901-6.10.1038/nm.1967
- 52. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM. Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther. 2008; 19:663-9.10.1089/hum.2008.033
- 53. Sharpe S, Polyanskaya N, Dennis M, Sutter G, Hanke T, Erfle V, et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol. 2001; 82:2215-23.
- 54. Koff WC, Parks CL, Berkhout B, Ackland J, Noble S, Gust ID. Replicating viral vectors as HIV vaccines summary report from IAVI sponsored satellite symposium, International AIDS Society Conference, July 22, 2007. Biologicals. 2008; 36:277-86.
- 55. Li F, Horton H, Gilbert PB, McElrath JM, Corey L, Self SG. HIV-1 CTL-based vaccine immunogen selection: antigen diversity and cellular response features. Curr HIV Res. 2007; 5:97-107.
- 56. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol. 2006; 6:417-23.10.1038/nri1840
- 57. D’Souza MP, Altfeld M. Measuring HIV specific T cell immunity: how valid are current assays? J Infect Dis. 2008; 197:337-9.
- 58. Chuenchitra T, Sukwit S, Gaywee J, Viputtikul K, Eamsila C, Tabprasit S, et al. The development of HIV research laboratories in the Royal Thai Army Medical Department. J Med Assoc Thai. 2005; 88 (Suppl 3):S317-24.
- 59. Fauce SR, Yang OO, Effros RB. Autologous CD4/CD8 co-culture assay: A physiologically-relevant composite measure of CD8(+) T lymphocyte function in HIVinfected persons. J Immunol Methods. 2007; 327: 75-81.
- 60. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, et al. Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes. J Virol. 2009; 83:3138-49.10.1128/JVI.02073-08
- 61. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, et al. Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol. 2009; 83: 791-801.
- 62. Excler JL. AIDS vaccine efficacy trials: expand capacity and prioritize. ‘Throughout Africa, Asia and Latin America state-of-the-art clinics and laboratories.exist where, 4 years ago, there were none’. Expert Rev Vaccines. 2006; 5:167-70.
- 63. Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, Tamashiro H, Osmanov S; WHO-UNAIDS Regional Consultation. Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian J Trop Med Public Health. 2008; 39: 766-84.
- 64. Ananworanich J, Phanuphak N, de Souza M, Paris R, Arroyo M, Trichavaroj R, et al. Incidence and characterization of acute HIV-1 infection in a highrisk Thai population. J Acquir Immune Defic Syndr. 2008; 49:151-5.
- 65. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 2008; 5:e157; discussion e157.10.1371/journal.pmed.0050157
- 66. Moore JP, Veazey RA, Barouch D. Can Vaccines and Microbicides be Co-developed? Presented at AIDS Vaccine 2008, Cape Town, South Africa, October 13-16, 2008. [Abstract RT01-01].
- 67. Plotkin SA. Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc. 2009; 12:2.